EUCTR2006-000799-33-DE进行中（未招募）不适用
A Study of the efficacy and safety of Rizatriptan 10 mg PRD in the treatment of acute migraine in patients with non satisfactory response to previous pharmacologic treatment - Rinotama Study
niversitätsklinikum Essen0 个研究点目标入组 200 人开始时间: 2006年7月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must fulfill the following conditions to qualifiy for enrollment into the trial:
- •4.1.1 18 to 65 years of age, both genders.
- •4.1.2 Willingness to comply with the investigators and protocol's instructions.
- •4.1.3 patient's signature on the informed consent document [each patient should be given ample time to read (or have read to them) the consent form, ask any questions they may have regarding the trial and have a clear understanding of the trial and the procedures involved prior to the signing of the consent form].
- •4.1.4 have a clinical diagnosis of migraine with or without aura according to IHS criteria at least one year prior to enrollment.
- •4.1.5 At screening at least two migraine attacks per month and no more than ten during the last three months prior to inclusion.
- •4.1.6 At screening a stable dose of prophylactic medication (including no prophylactic treatment) for at least two months and no change of prophylactic medication during active trial period.
- •4.1.7 Safe method of contraception. Oral contraception, double barrier method, IUP is considered safe as well as no active sexual behavior.
- •Reliable means of birth control is defined as:
- •a) Female sterilization; or
- •b) non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post menopausal (>1 year since last menstrual cycle); or
- •c) Male partner(s) who is (are) sterile prior to the female subject´s entry into the study and is (are) the sole sexual partner(s) for that female subject; or
- •d) Implants of levonorgestral within the lifetime of the implant; or
- •e) Injectable progesterone; or
- •f) Oral contraception (combined or progestogen only) started at least 2 months
- •prior entry in the study; or
- •g) Any intrauterine device (IUD) with published data showing that the highest expectedfailure rate is less than 1% per year; or
- •h) Double barrier contraception (e.g., combination of physical and chemical methods,
- •preferably a spermicide with either a condom or a diaphragm); or
- •i) Any other method of contraception with data documented in the product labeling as approved by regulatory agencies, or in the absence of approved labeling, in peer
- •reviewed studies, showing that the highest expected failure rate for that method is
- •less than 1% per year.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •patients with any of the following coonditions may not be enrolled into the trial:
- •4.2.1 Contraindication to triptans or Rizatriptan according to medical information sheet.
- •4.2.2. Patient has a history or clinical evidence of ischemic heart disease (e.g., angina pectoris of any type, history of myocardial infarction or documented silent ischemia) or symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm (including Prinzmetal's variant angina), or other significant underlying cardiovascular disease. Patient has uncontrolled hypertension. Patient has either demonstrated hypersensitivity to or experienced a serious adverse event in response to Rizatriptan or any of its inactive ingredients.
- •4.2.3 History of treatment failure for more than one triptan for the treatment of acute migraine attacks.
- •4.2.4 Medical relevant diagnosis of internal, neurological or psychiatric disease.
- •4.2.5 Any other headache, except tension type headache on 5 or less days a month within three months prior to screening.
- •4.2.6 A history of drug induced headache, medication overuse headache or any other addiction.
- •4.2.7 Any history of allergic hypersensitivity or poor tolerance to any components of the preparations used in this trial.
- •4.2.8Females of childbearing potential not using reliable means of birth control, pregnant or lactating females or expected/ planned pregnancy.
- •4.2.9. Participation (planned or current) in any investigational drug or device trial within the previous 30 days prior to screening visit.
- •4.2.10. Inability to understand the trial procedures, and thus inability to give informed consent.
- •unwillinglingness to accept the risk of of participating in the trial
- •4.2.11 History of allergy to sulfa drugs
- •4.2.12 Patient is pregnant or a nursing mother
研究者
相似试验
尚未招募
3 期
Rizatriptan versus Betahistin in Vestibular Migraine treatmentMigraineIRCT20230913059428N1Tabriz University of Medical Sciences40
招募中
Unknown
A Study on the Safety and Efficacy of Tirzepatide in People with Type 2 DiabetesType 2 DiabetesJPRN-UMIN000052214Kitasato University50
已完成
3 期
â??A clinical trial to study the beneficial effects of the drug â??â??Rupatadineâ?? in â??â??Allergic skin diseaseCTRI/2017/05/008624SRM University
已完成
2 期
The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients with Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical TrialChronic Inflammatory Demyelinating PolyneuropathyJPRN-UMIN000035753agoya University Hospital27
已完成
2 期
RECIPE TrialChronic Inflammatory Demyelinating PolyneuropathyJPRN-jRCT2041180037Iijima Masahiro25